Exodus Point Capital Management, LP Galectin Therapeutics Inc Transaction History

Exodus Point Capital Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$2.59 - $4.15 $108,888 - $174,474	-42,042 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$2.07 - $5.1 $87,026 - $214,414	42,042 New	42,042 $135,000
Q2 2019 Aug 14, 2019	SELL	$3.61 - $5.0 $255,782 - $354,270	-70,854 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$3.86 - $6.02 $139,940 - $218,249	36,254 Added 104.78%	70,854 $362,000
Q4 2018 Feb 14, 2019	BUY	$3.43 - $5.74 $118,678 - $198,604	34,600 New	34,600 $119,000

7.62M

61.2K

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $146M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Exodus Point Capital Management, LP, based on Form 13F filings with the SEC.

Stay updated on Exodus Point Capital Management, LP with notifications on news.